Dow Jones
34.053,94 -39,02 (-0,11%) Nasdaq
12.200,82 +384,50 (+3,25%) Nikkei 225
27.578,02 +175,97 (+0,64%) EUR/USD
1,0900 -0,0011 (-0,10%) BTC-EUR
21.629,38 -557,06 (-2,51%) CMC Crypto 200
537,43 -7,88 (-1,45%)
FibroGen, Inc. (0IL8.L)
| Chiusura precedente | 22,33 |
| Aperto | 0,00 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 0,00 - 0,00 |
| Intervallo di 52 settimane | |
| Volume | |
| Media Volume | N/D |
| Capitalizzazione | 16,706M |
| Beta (5 anni mensile) | 0,72 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -3,04 |
| Prossima data utili | 27 feb 2023 - 03 mar 2023 |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
FibroGen to Present at SVB Securities Global Biopharma Conference
SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16 at 3:40 PM Eastern Time. The live audio webcast of the event will be available to investors and other interested parties on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be availa
- GlobeNewswire
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8, at 1:05 PM Eastern Time. A live audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investors webpage at www.fibrogen.com. The replay will be available for approximately 30 days. About FibroGen
- GlobeNewswire
FibroGen Reports Third Quarter 2022 Financial Results
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of myelodysplastic syndromes with topline data expected 1H 2023Strong roxadustat volume growth in China of over 80% vs 3Q 2021Announced non-dilutive royalty monetization transaction with NovaQuest for $50 million of capital secured by 22.5% of roxadustat royalty revenue in t
